Ipsen gains FDA approval for fibrodysplasia ossificans progressiva therapy

17 Aug 2023
www.pharmaceutical-technology.com
Phase 3Drug ApprovalClinical Result
Ipsen gains FDA approval for fibrodysplasia ossificans progressiva therapy
Preview
Source: Pharmaceutical Technology
Ipsen’s Sohonos has a specific selectivity for the gamma subtype of retinoic acid receptors. Credit: Ipsen Pharma.
Ipsen has received approval from the US Food and Drug Administration (FDA) for its Sohonos (palovarotene) capsules to treat people with the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP).
It is approved as a retinoid to reduce the volume of new heterotopic ossification in adults and paediatric patients. Female patients must be eight years old and above to receive the treatment, and males must be at least ten.
Recommended Reports
Ipsen gains FDA approval for fibrodysplasia ossificans progressiva therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Naratuximab Emtansine in Follicular Lymphoma GlobalData
Ipsen gains FDA approval for fibrodysplasia ossificans progressiva therapy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Saracatinib Difumarate in Fibrodysplasia Ossificans Progressiva (Myositis Os... GlobalData
View allCompanies IntelligenceIpsen SAView all
The oral medicine Sohonos has a specific selectivity for the gamma subtype of retinoic acid receptors, which are skeletal development and ectopic bone regulators in the retinoid signalling pathway.
Sohonos mediates the interactions between the receptors, growth factors and proteins, and lowers the formation of new abnormal bone in FOP sufferers.
The FDA approval is based on the pivotal safety and efficacy data from the Phase III multicentre, open-label MOVE study in adult and paediatric patients.
This included 107 patients who were administered oral palovarotene and compared with untreated individuals from the Ipsen worldwide FOP natural history study.
The study showed that palovarotene successfully decreased the yearly volume of heterotopic ossification compared to no treatment beyond standard care.
Ipsen research and development head Howard Mayer stated: ” Developing medicines for rare diseases takes commitment and belief from everyone involved.
“We at Ipsen are sincerely grateful to the FOP community of patients and medical experts, as the first-ever treatment in the US for managing FOP would not be possible without their participation in the clinical trials and ongoing support.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.